Source-grounded facts extracted from NANOVIRICIDES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NANOVIRICIDES, INC. issued Series A Common Stock Purchase Warrants to purchase up to 3,571,429 shares of Common Stock and Series B Common Stock Purchase Warrants to purchase up to 3,571,4 of warrant to a certain institutional investor.
“The information contained above in Item 1.01 relating to the issuance of the Common Warrants and the shares of Common Stock issuable thereunder is hereby incorporated by reference into this Item 3.02.”
NANOVIRICIDES, INC. entered into Sales Agreement with EF Hutton LLC (effective 2024-04-05).
“On April 5, 2024, a new Sales Agreement (the “Sales Agreement”) was executed to name EF Hutton LLC as the sole sales agent (the “Agent”) and to remove B. Riley Securities, Inc. as a Sales Agent.”
NANOVIRICIDES, INC. amended a license with TheraCour Pharma, Inc. (effective 2024-02-12).
“nto a License Agreement (the “License Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Company for further development with respect to TheraCour’s research and development of services with respect”
NANOVIRICIDES, INC. entered into Line of Credit Agreement with Dr. Anil R. Diwan valued at $2,000,000 (effective 2023-11-13).
“on November 13, 2023, the Company and the Company’s President and CEO, Dr. Anil R. Diwan, entered into a Line of Credit Agreement whereby Dr. Diwan agreed to provide a standby Line of Credit to the Company in the maximum amount of $2,000,000.”
NANOVIRICIDES, INC. amended Extension Agreement with Dr. Anil R. Diwan valued at $2,000,000 (effective 2024-02-12).
“On February 12, 2024, the Company, pursuant to Article 2.5 of the Company’s Line of Credit Agreement with Dr. Anil R. Diwan, signed an Extension Agreement which extended the maturity date of the Company’s Line of Credit from December 31, 2024 to December 31, 2025.”
NANOVIRICIDES, INC. amended Amendment with TheraCour Pharma, Inc. (effective 2024-02-13).
“Amendment to Coronavirus License Agreement As previously disclosed, on September 9, 2021, NanoViricides, Inc. (the “Company”) entered”
NANOVIRICIDES, INC. entered into License Agreement with TheraCour Pharma, Inc. (effective 2021-09-09).
“NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with TheraCour Pharma, Inc. (“TheraCour”) for an exclusive, worldwide license to the Company for further development with respect to TheraCour’s research and development of services with respect to treatments for coronavirus derived human infections.”
NANOVIRICIDES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024 at the 2024-01-13 meeting.
“Proposal 4 – To ratify the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024: Votes For Votes Against Votes Abstained 9,165,259 152,847 125,594”
NANOVIRICIDES, INC. shareholders approved Approval of an award of 10,204 Series A Preferred Shares to Anil Diwan in connection with the extension of his employment as the Company’s President at the 2024-01-13 meeting.
“Proposal 3 – Approval of Convertible Preferred Stock Grant to Anil Diwan: Votes For Votes Against Votes Abstained Broker Non-Votes 5,508,046 844,079 34,609 3,056,966”
NANOVIRICIDES, INC. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2024-01-13 meeting.
“Proposal 2 – Advisory Vote on Compensation of Named Executive Officers: Votes For Votes Against Votes Abstained Broker Non-Votes 5,572,378 788,423 25,933 3,056,966”
NANOVIRICIDES, INC. shareholders approved Re-election of Anil Diwan as a Class I Director for a two-year term expiring at the 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal at the 2024-01-13 meeting.
“Proposal 1 – Election of Director - Re-Election of Anil Diwan as a Class I Director: Votes For Votes Against Votes Abstained Broker Non-Votes 5,590,467 308,092 488,175 3,056,966”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.